Alkermes (ALKS) announced after the bell Thursday that its Phase 3 study of ALKS 5461 met its primary endpoint. The drug showed significantly reduced symptoms of depression in patients with major depressive disorder.
from RTT - Hot Stocks http://ift.tt/2eqQUcc
via IFTTT
No comments:
Post a Comment